Phio Pharmaceuticals Corp. PHIO 深 滬
已收盤 05-08 16:00:00 美东时间
1.07
-0.070
-6.14%
華盛通- 最 高1.15
- 今 開1.15
- 成交量 32.43万股
- 最 低 1.04
- 昨 收 1.14
- 總市值 1.24万
- 52周最高 4.1899
- 市盈率 靜 --
- 換手率 2791.56%
- 52周最低 0.8127
- 委 比 95.24%
- 總股本 1.16万
- 歷史最高 3118.50
- 量 比 1.82
- 振 幅 9.65%
- 歷史最低 0.8127
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of $(0.47) per share from the
05-08 04:51
Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply
Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous carcinomas. In its Phase 1b trial, Phio has reported that 22 patients completed treatment
03-30 19:22
Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply
Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply Phio Pharmaceuticals signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials. Deal covers production of PH-762 for both clinical supply and commerci
03-30 19:03
Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b clinical study (NCT
03-23 19:17
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma Phio said Phase 1b results from its escalating-dose study of intratumoral PH-762 (NCT 06014086) in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma will
03-23 19:04
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Phio Pharmaceuticals Corp. will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series with a live presentation and Q&A on Monday, March 9, 2026 at 10:00 a.m. EDT
03-05 20:03
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms Phio Pharmaceuticals Corp. amended CEO Robert J. Bitterman’s employment agreement. The update raises his annual target bonus opportunity to 50% of base salary (from 40%) and provides 12 months of base-salary severance if he i
02-19 05:01
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
The Safety Monitoring Committee Concluded Its Planned Safety Review For All Patients Treated With The INTASYL compound PH-762 In Phio Pharmaceuticals' Phase 1b Trial, No Serious Adverse Events Or Dose-limiting Toxicities Identified
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders
02-10 20:09
